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The nicotinic acetylcholine receptor (AChR) is a large membrane protein found in muscle
cells. It is involved in the transformation ofacetylcholine packets into a membranedepolarization,
which thereby leads to a muscle twitch. This large, complex molecule is the target of the
autoimmune attack in myasthenia gravis, and much has been learned in the past decade about
myasthenia by the induction of autoimmunity to AChR in experimental animals. Experimental
autoimmune myasthenia gravis (EAMG) has been produced in a variety of animals by
immunization with AChR or AChR-like material, or by the passive transfer of anti-AChR
antibodies or lymphocytes from afflicted animals into normal animals. EAMG is a remarkably
faithful model ofhuman myasthenia and has provided much information about how the immune
response to AChR progresses and how weakness and damage to the neuromuscular junction
ensue. EAMG has also allowed the development ofa number ofrevolutionary forms oftreatment
in which only the abnormal response to AChR is restrained, and other necessary immune
functions are left intact. These advances in treatment are not far from being tested in human
myasthenia gravis. The experience gained in applying these concepts in EAMG and human
myasthenia will be helpful in developing similar forms of treatment for other autoimmune
diseases.
The study of the experimental model of myasthenia, experimental autoimmune
myasthenia gravis (EAMG), has been rewarding because of its great applicability to
both experimental and human disease processes. EAMG has also proven invaluable
because of insights gained into membrane receptor function, antibody effector
mechanisms, and immunoregulation. Myasthenia gravis and EAMG are unique
among autoimmune diseases in that: (1) the target of the autoimmune attack, the
acetylcholine receptor (AChR), has been purified, characterized [1], and sequenced
[2,3]; (2) the experimental model is remarkably faithful to the human disease [4,5];
and (3) a wide variety ofligands, both agonists and antagonists, for the AChR, as well
as natural sources of large amounts of AChR (i.e., from electric fishes and eels), is
available. Because of the special advantages of this system, experimental myasthenia
has been the subject of intensive research over the past decade. Some areas in this
research most applicable to the neurologist will be reviewed here.
EAMG: INDUCTION, CHARACTERIZATION, AND DEVELOPMENT
There are four ways that experimental myasthenia has been induced: immunization
with acetylcholine receptor, passive transfer of poly- or monoclonal anti-AChR
antibodies, passive transfer of AChR-sensitized cells, and immunization with the
"internal image" ofAChR (anti-AChR ligand antibodies).
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Immunization with AChR
EAMG has been induced in rats [6], guinea pigs [7], rabbits [8], monkeys [9], and
mice [4,10] by immunization with AChR. Generally, EAMG induced by active
immunization with AChR has been studied using AChR from various animals with
electric organs, particularly Torpedo californica, Electrophorus electricus, and Narke
japonica; however, immunization with mammalian AChR has also induced EAMG
(e.g., immunization of rats [11] or BALB/c mice [12] with rat AChR). There is a
considerable degree of variability in the manifestations of EAMG, ranging from no
clinical disease even after multiple boosting immunizations (e.g., many mouse strains)
to severe weakness progressing after only one immunization to death (e.g., rabbits).
EAMG has been most frequently studied in rats and mice. After immunization with
3.5 to 350 pmoles (0.8-80 micrograms) ofAChR, rats developed a biphasic illness [5],
with an initial weakness a few weeks after the initial immunization associated with a
cellular infiltrate in the muscle. Later in the course of the disease, the rats were once
again weak, but pathology only revealed a flattening of the normally frondlike
postsynaptic neuromuscular junction without a cellular infiltrate. The evolution of the
two phases of neuromuscular junction damage are not well understood, and a correlate
of the early phase of damage has not been found in human myasthenia gravis. The
early phase ofcellular infiltration has not been seen in EAMG in mice. Another major
difference between EAMG in rats and mice is that the severity of weakness in mice is
much less than in other experimental animals studied; this is most likely due to
variations in the immune responsiveness to AChR between the animals, similar to the
variation in the clinical severity of EAMG in different mouse strains [13]. EAMG has
been induced in rodents primarily through the use of fish AChR (i.e., the immunogen
has not been the actual autoantigen, and the development of clinical weakness thus
depends on the extent of cross-reaction of the immune response to fish AChR with rat
or mouse AChR). In a study of Lewis rats immunized with Torpedo AChR [14], there
was a several-week delay in the rise to a plateau of anti-rat AChR antibody compared
to anti-Torpedo AChR antibody, and the titers of the latter were only 1 percent of the
former.
A number ofconfirmatory tests have been used to support the postulate that EAMG
resembles human myasthenia. In both diseases there is: (i) a marked decrease in the
number of functional AChRs (as detected by bungarotoxin binding to AChR), (ii) a
decremental response ofthe muscle action potential to repetitive nerve stimulation, (iii)
a decrease in the amplitude but not frequency of miniature end-plate potentials, and
(iv) a dramatic improvement in strength with cholinesterase inhibitors, and worsening
with AChR blockers such as snake toxins and curare. The extremely high affinity of
snake toxins, such as alpha-bungarotoxin from the Formosan many-banded krait, for
the AChR allows the quantification ofAChRs at the neuromuscular junction [15]. An
electron-dense material such as horseradish peroxidase (HRP) is coupled to alpha-
bungarotoxin (BTX), the HRP-BTX is applied to the muscle, carefully washed away,
and the electron-dense particles can be visualized at the neuromuscular junction by
electron microscopy; their density correlates with the number of AChRs. This loss of
BTX binding can also be measured by incubating muscle homogenates with radiola-
beled BTX, and expressing AChR content as the number of counts bound per mg of
protein. Both electromyography (EMG) and the amplitude of miniature end-plate
potentials (MEPPs) measure electrophysiological correlates to the loss of AChR. In
170EXPERIMENTAL MODELS OF MYASTHENIA GRAVIS
the former [16], repetitive stimulation, usually at 5-20 Hz, is applied to the motor
nerve of the human or anesthetized animal, and a recording electrode in the muscle
innervated by the nerve detects the response of the muscle. In normal animals a
repetitive impulse can be maintained, often for minutes, without a change in the
amplitude of the evoked muscle response; in MG and EAMG there is a characteristic
drop, or decrement, in the amplitude with repetitive stimulation. In MEPP studies, the
frequency and amplitude ofthe electrical response ofmuscle membranes in response to
spontaneous release ofacetylcholine packets is measured; in MG and EAMG there is a
decrease in the amplitude but not frequency of the end-plate potentials. Finally, the
most frequently used confirmatory test for human myasthenia is the Tensilon test, in
which pyridostigmine, a short-acting cholinesterase inhibitor, is injected intravenously,
and the clinical response is tested. When weakness in a patient is due to MG, there is
usually a dramatic and instant positive response to Tensilon; this type of response is
also seen in EAMG. In addition, both EAMG and MG clinically deteriorate by the
injection of AChR antagonists, such as d-tubocurare, at doses that do not affect the
disease-free subject.
One major difference between EAMG and MG is the absence ofthymic abnormali-
ties in the former. The obvious, but untested, corollary to that statement is that the
initiating abnormality in MG is in the thymus, and the damage to the nicotinic AChR
ofmuscle is secondary. "Myoid" tissue with BTX-binding AChR has been found in the
thymus [17], and the induction ofthe anti-AChR autoimmunity of MG in the thymus
has been postulated [18]. The immunological activity of the thymus in myasthenia is
deranged; histology of this organ in the majority of myasthenics is abnormal, and
staining of the thymus reveals that both B- and T-lymphocytes are grouped together in
patterns identical to those of lymphoid follicles. These cells are able to make
anti-AChR antibody in vitro [19]. The hypothesis that the thymus is crucial for the
induction of myasthenia is attractive but remains unproven.
Induction ofExperimental Myasthenia by Passive Transfer ofAntibody
One of the most convincing early pieces of evidence that the pathogenesis of
myasthenia gravis was antibody-mediated effects on the AChR was the production of
the disease in rodents by transfer of serum from myasthenics into mice [20] and rats
[21]. Since that time, the development of techniques for producing monoclonal
antibodies [22] has led to the production of monoclonal anti-AChR antibodies in a
number of laboratories [23,24,25,26]. These monoclonal antibodies (mcAbs) were
then injected into animals; some mcAbs produced weakness, and some did not.
Although it was hoped that the in vitro characteristics of the monoclonal antibodies
(that is, affinity, determinant on the AChR to which they bound, subclass) could be
correlated with the in vivo effect, this turned out not to be the case. Monoclonal
antibodies directed against a number of different epitopes are able to induce disease;
some investigators feel that there seem to be at least two types of disease induced,
depending on the specificity of the mcAb used [27]. The "hyperacute" type is
characterized by the development ofweakness within a few hours after injection of the
mcAb and is not associated with inflammatory infiltrates within the muscle. This form
of passively transferred myasthenia is induced by mcAbs directed against the
acetylcholine binding site of the AChR, which is very close or identical to the
bungarotoxin binding site [27,28]. This group of anti-AChR antibodies is especially
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interesting clinically because it is not tested for in the routinely available clinical assay
(i.e., since anti-AChR antibodies are generally measured by immunoprecipitation
using AChR labeled with radio-iodinated BTX, antibodies of this specificity are
prevented from binding in this assay and are not measured). The other type of
experimental myasthenia passively transferred with mcAbs resembles that induced
with polyclonal antisera; it develops more slowly and is associated with inflammatory
lesions at the endplates [26,29]. This form ofmyasthenia is caused by mcAbs directed
against sites on the AChR other than the BTX-binding site. A problem further
complicating the situation is a marked difference in sensitivity to mcAb passive
transfer ofEAMG among various animals. These differences cannot be predicted by in
vitro studies. For example, the monoclonal anti-AChR antibody, 5.5, which has
activity in vitro against both mouse and chick muscle [30], induces paralysis and death
on injection into chicks [28] but has no effect at all upon mice, even with huge
intravenous doses [31].
Passive Transfer ofAChR-Sensitized Cells
Experimental myasthenia has also been produced by transfer of cells from animals
with EAMG to naive animals [18,32,33]. These experiments are generally difficult
and complicated, and the efficacy of cell transfers has been low, especially relative to
antibody transfers. All experiments in which successful transfers occurred included
both B cells and T cells, sometimes associated with immunization with AChR.
Certainly, direct effector T-cell mediation of AChR damage seems unlikely, since
highly purified anti-AChR T cells at relatively high concentrations were completely
ineffective in inducing disease in rats [18]. Many objections could be raised to the
conclusions, based on these studies, that there is definitely no direct effect ofT cells or
their products on the AChR, but certainly the major effector ofpathogenicity seems to
be antibody. The predominant contribution ofthe T-lymphocyte to this process is most
likely its control of the quantity and quality of anti-AChR antibody production (see
below) [34].
Induction ofExperimental Myasthenia by Immunization with the "Internal Image"
ofAChR
Jerne's network hypothesis postulates the existence of a subset of anti-(antibody)
antibodies, called anti-idiotypic antibodies, that are structurally related to the original
antigen; he labeled this population the "internal image" ofthe antigen. In a number of
receptor systems [35,36], antibodies to receptor ligands have been shown to mimic the
receptor in that injection of these anti-ligand antibodies has been able to induce
anti-idiotypic antibodies that bind to the receptor (i.e., mimic ligand). In a series of
experiments using bisQ, a structurally constrained ligand of the AChR, anti-AChR
antibodies and EAMG have been induced by immunization with anti-bisQ antibodies
[37,38]. We extended this work by using a naturally occurring ligand of the AChR,
cobratoxin [39]. Rabbits and mice were immunized with affinity purified anti-
cobratoxin antibodies. All animals developed anti-AChR antibodies, and some devel-
oped weakness and electromyographic abnormalities characteristic of EAMG. The
study of this disease will be greatly facilitated by the use of a monoclonal anti-
neurotoxin antibody that is the "internal image" ofthe AChR [40].
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EAMG: IMMUNOREGULATION
When purified Torpedo or Electrophorus AChR is injected into mice or rats, it
behaves like other soluble protein antigens. The antibody it induces is thymus-
dependent [41], and both AChR-specific helper-proliferative T cells [42] and suppres-
sor T cells [43] participate in controlling the production of anti-AChR antibody.
Shortly after immunization, helper-proliferative T cells appear in the lymph nodes
draining the sites of immunization, along with B cells, either those with anti-AChR
immunoglobulin on their surface or those which have matured into anti-AChR
antibody-producing plasma cells. AChR-specific B cells in vitro are responsive to
T-cell help, which can be provided either by the T cells themselves or by supernatants
from AChR-specific helper-proliferative T-cell lines [42]. The response is dependent
on the presentation of AChR on the surface of macrophages to T cells [44]. The
AChR-specific helper-proliferative T-cell response can be measured in a number of
ways: degree ofproliferation in the presenceofsoluble AChR, amountofhelp provided
for primed B cells to make anti-AChR antibody, AChR-induced lymphokine release
[58], or swelling when AChR is injected into the ear or foot [41,45]. I-A antigens on
the surface ofmacrophages are involved in the generation ofthe anti-AChR response,
and administration of anti-I-A monoclonal antibodies decreases the amplitude of the
response [46]. Suppressor cells specific for the AChR appear [43,47,48], although the
stimuli for their generation and optimal function are unknown. It seems likely that the
differences in EAMG among different mouse strains are related to variations in
immunoregulation [13], particularly suppressor T cells.
Our current knowledge about immunoregulation in EAMG has been gained by
focusing on the early events after eel (Torpedo or Electrophorus) AChR immuniza-
tion. The antigen used in these in vitro studies has been eel AChR, which is readily
available and easily purified. The autoimmune response is of more interest, however,
than that generated against mouse AChR. This response is difficult to measure
accurately because purified mammalian receptor is very difficult to obtain in large
enough quantities to study. Generally, the anti-rodent AChR antibody response is
measured by immunoprecipitation of muscle homogenates labeled with iodinated
bungarotoxin. The amount of antibodies present in the serum measured in this way is
at least one hundred times lower than the antibody content directed against Torpedo
AChR, even at the height of muscle weakness. T cells require more purified antigens
for stimulation experiments, and thus, an adequate study of T-cell responses to
mammalian AChR in EAMG has not been done. Recently, synthetic peptides of the
AChR have been produced which represent areas of the molecule that are able to
induce EAMG upon immunization [49,50]. These peptides are portions ofthe AChR
molecule that function in snake toxin binding; their amino acid sequences are highly
preserved among species. The immune responses to these peptides are probably
important in the induction and propagation ofmyasthenia, and their study will provide
valuable information about immunoregulation in EAMG and MG.
NOVEL FORMS OF TREATMENT SUCCESSFUL IN EAMG AND
THEIR APPLICABILITY TO HUMAN MG
All current forms oftreatment ofMG are "antigen non-specific"; that is, despite the
fact that it is known that the AChR is the autoantigen in this autoimmune disease, no
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available therapy makes use of that knowledge. EAMG is an ideal model to test new
forms of treatment, especially "AChR-specific" ones in which only the immune
response to AChR is blunted, and not immunity to other antigens. The two most
promising areas ofwork center around suppressor T cells and anti-idiotypic antibodies.
(Some interesting "AChR non-specific" forms of therapy have been attempted, such
as treatment with monoclonal anti-I-A antibodies [46] or monoclonal anti-helper
T-cell antibodies [51].)
It has been shown that suppressor T cells suppress the immune response to the
AChR in vitro [43,47,48]. In the only in vivo study to date, AChR-specific suppressor
T cells, injected into mice prior to immunization with Torpedo AChR, diminished the
anti-Torpedo AChR antibody titer and electromyographic evidence ofdisease but had
no effect on the immune response to an irrelevant antigen [43]. This specificity is
highly desirable, as all AChR non-specific forms of immunosuppression will suppress
beneficial forms of immunity (e.g., to pathogens and tumors). Recent studies on
AChR-specific suppressor T-cell hybridoma factors that are active in vitro raise the
possibility that such purified material may be used in vivo [52]. Suppressor T cells and
factors most probably act on the AChR-specific helper-proliferative-inducer cells and
function in blocking the ability of these cells to help B cells make antibody against
AChR. There are two major stumbling blocks to the rapid expansion ofthis work and
its application to human disease. First, unlike B-cell products (i.e., antibodies), there
are no rapid screening assays for T-cell products such as suppressor factors. Suppres-
sion must be tested on T-cell functions such as proliferation or in vitro help, assays
which require five or six days to develop and only allow a limited number of products
and conditions to be tested. Second, very little is understood about antigen-specific
T-cell factors, especially in the immune response to complex proteins; most studies
have been performed with antigens such as haptens or sheep red blood cells. These
problems, however, are purely methodologic, and it is likely that T-cell suppression will
prove applicable to therapy ofmyasthenia and other autoimmune diseases.
Anti-idiotypic antibodies are really autoantibodies in that they are directed against
a "selfantigen" (i.e., idiotypicdeterminants, present on the antigen combining portion
of immunoglobulin). Anti-idiotypic antibodies in the anti-AChR response, thus, are
those antibodies with specificity for the portion of anti-AChR antibodies that are
involved with AChR binding. A commonly used and well-accepted assay for anti-
idiotypic antibodies is blocking of binding of the idiotype to the antigen (i.e., in the
AChR system, blocking ofthe binding ofanti-AChR antibodies to AChR). A number
of investigators have studied anti-idiotypic antibodies in MG and EAMG
[53,54,55,56,57]; their results and conclusions vary depending on the system studied,
particularly whether the anti-idiotypic antibodies were developed against a polyclonal
versus a monoclonal preparation. In the only successful experiment with anti-idiotypic
antibodies in vivo, ongoing myasthenia, induced by passive transfer of a monoclonal
antibody, has been reversed by treatment with polyclonal anti-idiotypic antibodies
[28]. This success in a monoclonal system augurs well for successful treatment in the
polyclonal response, since anti-idiotypic antibodies to polyclonal anti-idiotypic anti-
bodies have been produced in a number of the above-referenced studies. Again, the
barriers to the application of these techniques to the human disease are purely
methodological, and anti-idiotypic antibodies may well find a useful place in antigen-
specific therapy for myasthenia gravis and other autoimmune diseases in the future.
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